Boston Scientific (NYSE:BSX) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Representative Gilbert Ray Cisneros, Jr. sold shares of Boston Scientific Corporation for an amount between $1,001 and $15,000 on July 31st, 2025.
• Boston Scientific reported a 22.8% increase in quarterly revenue compared to the same period last year, reaching $5.06 billion with an EPS of $0.75.
• Several analysts have recently raised their price targets for Boston Scientific, with Citigroup updating their target to $125.00 and Barclays to $133.00.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on August 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on July 31st. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of W.R. Berkley NYSE: WRB on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Medpace NASDAQ: MEDP on 7/24/2025.
• Sold $1,001 - $15,000 in shares of Avantor NYSE: AVTR on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Gulfport Energy NYSE: GPOR on 7/18/2025.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 7/9/2025.
• Purchased $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 7/9/2025.

Boston Scientific Price Performance

BSX stock opened at $103.15 on Friday. Boston Scientific Corporation has a 52 week low of $77.29 and a 52 week high of $108.94. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a fifty day simple moving average of $103.56 and a two-hundred day simple moving average of $102.09. The firm has a market capitalization of $152.84 billion, a P/E ratio of 61.40, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business earned $0.62 earnings per share. Boston Scientific's quarterly revenue was up 22.8% compared to the same quarter last year. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several research reports. Oppenheimer increased their price objective on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research report on Thursday, July 24th. Citigroup restated a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Barclays raised their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Finally, Morgan Stanley raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Two investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average price target of $117.50.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 345,029 shares of company stock worth $35,976,603. Corporate insiders own 0.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Colonial Trust Co SC boosted its stake in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares in the last quarter. Investment Management Corp VA ADV acquired a new stake in Boston Scientific in the 4th quarter worth approximately $25,000. Sunbeam Capital Management LLC acquired a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter worth approximately $26,000. Finally, FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $26,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.